Response Criteria for Vitreous Seeds

CR: Type 0 or I regression, or Type II or III regression demonstrating clinical stability on fundus photography for 6 months or more. Additional therapy is not indicated in these patients.

PR: Unequivocal improvement in seeding as indicated by reduction in the number or density of seeds and/or Types II or III regression that have demonstrated clinical stability on fundus photography for less than 6 months.


Continue Reading

SD: No evidence of unequivocal improvement or progression of seeding.

PD: Unequivocal progression of seeding as indicated by an increase in the “number or density of seeds, conversion from dust to spheres, or the presence of new preretinal tumors.”5

Response Criteria for Subretinal Seeds

CR: No visible subretinal fluid or subretinal seeds, or calcification of all subretinal seeds for 6 months or more.

PR: Unequivocal improvement in subretinal seeding as indicated by reduction in the number or density of subretinal seeds without complete calcification, as well as decreased subretinal fluid.

SD: No evidence of unequivocal improvement or progression of seeding.

PD: Unequivocal progression of seeding as indicated by an increase in the number or density of seeds, and/or an increase in subretinal fluid.

In conclusion, these guidelines are intended to “standardize the language and assessment of tumor response across all studies of retinoblastoma therapy,” the authors wrote.5 “In the future, we encourage treatment centers to prospectively evaluate and validate the RB-RECIST recommendations in the context of relevant imaging techniques and therapeutics for retinoblastoma.”

Cancer Therapy Advisor sought to learn more about the RB-RECIST guidelines in an interview with lead author Jesse L. Berry, MD, associate professor of ophthalmology at the Keck School of Medicine at the University of Southern California (USC) in Los Angeles, and Associate Director of Ocular Oncology at Children’s Hospital Los Angeles and the USC Roski Eye Institute.